Boston Scientific Bronchial Thermoplasty Treatment Recognized By American College Of Allergy, Asthma And Immunology

Jul 09, 2015, 09:00 ET from Boston Scientific Corporation

MARLBOROUGH, Mass., July 9, 2015 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that Bronchial Thermoplasty (BT) delivered by the Alair System has received support from the American College of Allergy, Asthma and Immunology (ACAAI). BT is an outpatient procedure proven to reduce asthma attacks in adult patients with severe asthma.1 This demonstrates a growing clinical acceptance among allergists for this novel, procedure-based treatment option for severe asthma.

"Allergists see a wide range of adult asthma patients – some of whom suffer from asthma that can not be controlled with available therapeutic regimens," said allergist James Sublett, MD, ACAAI president. "The scientific literature supports bronchial thermoplasty as a therapeutic consideration for some carefully chosen patients with severe, difficult-to-control asthma. In addition, ACAAI recommends that insurers provide coverage for bronchial thermoplasty for those adult patients who meet the stringent requirements."

According to the recommendation, ACAAI supports the indicated purpose that patients with severe asthma, who continue to have symptoms of the disease despite maximal medication treatment, may benefit from Bronchial Thermoplasty as a therapeutic option. BT delivered by the Alair System is the first safe and effective non-drug asthma treatment for adult patients with proven benefits lasting out to at least five years.2 As part of the recommendation, ACAAI also recommends healthcare insurers provide coverage for Bronchial Thermoplasty for carefully selected patients with severe asthma.

"In addition to improving outcomes, Bronchial Thermoplasty is a cost-effective treatment," said David Pierce, president, Endoscopy, Boston Scientific. "We are pleased to receive support from ACAAI for BT as an accepted therapeutic option for patients with severe asthma whose symptoms are uncontrolled despite an escalating drug regimen."

ACAAI joins a growing list of society and advocacy groups that support Bronchial Thermoplasty as a treatment option, including Global Initiative for Asthma (GINA), American College of Chest Physicians (CHEST), British Thoracic Society (BTS), INTERASMA, Allergy and Asthma Network (AAN), and Asthma and Allergy Foundation of America (AAFA).

Bronchial Thermoplasty is not meant to replace daily maintenance medications, but works with them for better management of the disease.

To learn more visit www.BTforAsthma.com.

1 Castro M, et al, for the AIR2 Trial Study Group. Am J Respir Crit Care Med. 2010;181:116-124.

2 Wechsler M et al. J Allergy Clin Immunol. 2013 Dec;132(6):1295-302

About Bronchial Thermoplasty (BT) Bronchial Thermoplasty delivered by the Alair System delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. It is designed to decrease the ability of the airway to constrict, thereby reducing frequency and severity of asthma attacks and associated emergency room (ER) visits.

About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding markets for our products and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Nisha Deo 408-893-9243 (cell) External Communications Boston Scientific Corporation Nisha.Deo@bsci.com

Susie Lisa, CFA 508-683-5565 (office) Investor Relations Boston Scientific Corporation investor_relations@bsci.com

SOURCE Boston Scientific Corporation



RELATED LINKS

http://www.bostonscientific.com